Network and expertise

The Fraunhofer CIMD combines the interdisciplinary Fraunhofer expertise of three core institutes and approximately 14 partner institutes. In addition, the Fraunhofer CIMD has a large number of collaborations with universities, hospitals and non-university institutions, as well as with partners from industry.

We use the Fraunhofer-specific strengths in the field of medical translation and inter- and transdisciplinarity to gain scientific insights into the early detection, diagnosis and new therapeutic options for immune disorders and to optimize patient care.

Future projects with other Fraunhofer institutes are possible at any time. Interested parties from science and industry are also welcome to contact us and discuss possible synergies.

Below, we would like to give you a brief overview of the expertise at Fraunhofer CIMD.

You can also find more information about our research projects, collaborations and events.

Overview of the expertise bundled at Fraunhofer CIMD

Expand all Close all

Biomarker

Biomarker analysis and development

Biobank
Biopsies (synovia, pleura, liquid biopsy)
Cell isolation
Proteome, metabolome and lipidome analysis
Epigenetics
sequencing
Next-generation cytometry
biosensors
Single cell diagnostics
OMICS platforms
LC-MS/MS analytics

drug discovery

Cryo-electron microscopy
Multi-epitope ligand mapping
Next-generation cytometry
Mass spectrometry
Cell-based assays
High-throughput screening
Drug design
Medicinal chemistry

therapeutic concept

Development planning and target product
Profiles of innovative concepts and products
Cost efficiency
Genetic cell therapy
Therapeutic antibodies
Nucleic acid-based therapy
Chemically defined therapeutics
Vaccines
OMICS technologies
CyTOF technologies

preclinical

Cell-based human in vitro systems (e.g. “lab on a chip”, 3D tissue models)
Human organotypic systems (e.g. ex vivo tissue cultures)
Animal models (e.g. CRISPR/Cas9-based)
Zebrafish models
Insect models
Imaging techniques
Bioanalytics
GLP testing (safety pharmacology, toxicology)

GMP production

Process development and GMP-compliant production (e.g. biopharmaceuticals, cell and gene therapeutics, drug candidates, master and working cell banks)
Formulation, sterile filling
Low-energy electron beam
Quality assurance

Clinical studies

Conducting Phase I and Phase II clinical trials

Clinical Research Center
Sponsor function
Phase I units
PoC studies, Phase I/II studies, Phase IV studies
Subject database
Clinical project management
Clinical pharmacology
Regulatory Affairs
Pharmacovigilance
Biostatistics
data management

Zulassung

Market approval

Regulatory expertise from preclinical to market approval
Health Technology Assessment and AMNOG procedure

Biobank

Biobanks: High-quality biomaterials

High-quality biomaterials are the basis for meaningful results in the field of medical research. In the section of immune disorders, however, their acquisition is often a limiting factor. Blood, tissue, stool and urine samples, among others, are collected and stored in the biomaterial banks of the Fraunhofer IME, the Fraunhofer IZI and the Fraunhofer ITEM. These biomaterials can be used for scientific research upon request.

4D Clinic

4D Klinic

Data intelligence

DATA INTELLIGENCE

Early detection and personalized treatment of immune disorders

Our brochure provides an insight into the work of the Fraunhofer CIMD: we present the field of immune disease indications, our combined expertise, the path from medical need to new drug, and our biomaterial databases.

From medical need to new medication

The development of a new drug is a legally prescribed, multi-stage process. It takes an average of more than 13 years from the initial idea to the first approval. A large part of this time is spent on studies to test the efficacy and tolerability of the drug and to determine how it can best be used.

We can draw on these patient materials in the biobanks of the three institutes

Diagnosis

Ataxia teleangiectasia
Asthma (LPS Challenge)
Asthma (Rhinovirus Challenge)
Chronic inflammatory bowel disease
COPD GOLD 1-4
Eosinophilic fasciitis
Granulomatosis with polyangiitis
Lupus erythematosus
Psoriatic arthritis
Psoriasis vulgaris
Rheumatoid arthritis
rhinitis
Sarcoidosis
Spondyloarthritis
Systemic sclerosis
Tumor

Sample type

Bronchoalveolar lavage
Citrated plasma
DNA, RNA
EDTA whole blood
Skin biopsies
Heparin plasma
Lung biopsies
Nasopharyngeal lavage
PAXgenes
PBMCs
serum
sputum
Stool, urine
Synovial fluid and synovia (tissue)
Cells from BAL (bronchoalveolar lavage), NAL (nasal lavage) and sputum
Cell culture supernatants

Network and expertise

Overview of the expertise bundled at Fraunhofer CIMD

Biomarker

Biomarker analysis and development

drug discovery

drug discovery

therapeutic concept

therapeutic concept

preclinical

preclinical

GMP production

GMP production

Clinical studies

Conducting Phase I and Phase II clinical trials

Zulassung

Market approval

Biobank

Biobanks: High-quality biomaterials

4D Clinic

Data intelligence

Early detection and personalized treatment of immune disorders

Theme brochure

From medical need to new medication

Background knowledge: the phases of drug development

We can draw on these patient materials in the biobanks of the three institutes

Diagnosis

Sample type

board of directors

central office

project leader

Institute

Projects

Network